DISCLAIMER: This guide is educational content intended for research and informational purposes only. LL-37 is not FDA-approved for therapeutic use and is available only as a research peptide in most jurisdictions. This is not medical advice. Always consult with a healthcare provider before using any research peptide, especially if you have autoimmune conditions, active malignancies, or are taking immunosuppressive therapy. The author assumes no liability for misuse or adverse effects.
LL-37 is the only human cathelicidin antimicrobial peptide, naturally produced by neutrophils, epithelial cells, and keratinocytes as part of innate immunity. Beyond its antimicrobial properties, LL-37 demonstrates immunomodulatory, wound-healing, and anti-inflammatory potential. It works through multiple mechanisms: disrupting pathogenic membranes, activating TLR4 signaling, recruiting immune cells, and promoting tissue repair through EGFR transactivation and VEGF upregulation.
Available routes include injection (subcutaneous or intramuscular), topical application, and nasal administration. Injectable protocols dominate research and produce the most consistent systemic effects, making them the focus of this guide.
Cost Range: $40–$180/month depending on dosage and source.
Dose Range: 100–500 mcg per injection
Frequency: Once daily
Route: Subcutaneous or intramuscular injection
Standard Starting Dose: 250 mcg daily
Reconstitution (if lyophilized):
- Use bacteriostatic water or sterile saline
- Reconstitute at a ratio of 1 mcg/µL (e.g., 2.5 mL water for 2,500 mcg vial = 1 mcg per 0.001 mL or 1 mcg per µL)
- Draw calculated volume into syringe (e.g., 250 µL for 250 mcg)
- Inject subcutaneously into abdomen, thigh, or upper arm; rotate injection sites daily
- Store reconstituted solution at 2–8°C; use within 14 days
Injection Technique:
- Use 27–30 gauge insulin syringe for subcutaneous injection
- Pinch skin, insert at 45° angle, inject slowly over 5–10 seconds
- Rotate sites to prevent lipohypertrophy
- Optimal injection time: morning or early afternoon
Concentration: 0.1–1% formulation
Frequency: Twice daily (morning and evening)
Application: To affected area only (wounds, skin lesions, infected tissue)
Amount: 0.5–1 gram per application, gently massaged into area
Duration: Continue until healing observed or up to 12 weeks
Topical Guidelines:
- Clean area gently before application
- Allow 2–3 minutes for absorption before covering with dressing
- Use medical-grade formulations to minimize irritation
- Suitable for diabetic foot ulcers, chronic wounds, and localized skin infections
Concentration: 0.1–0.5% intranasal spray
Frequency: 1–2 sprays per nostril, twice daily
Duration: 4–8 weeks for mucosal infections or immune support
Primary Indication: Diabetic foot ulcers, surgical wounds, chronic wounds, gingival disease
Protocol:
- Dose: 250 mcg injection daily OR 0.5% topical cream twice daily
- Cycle Length: 12–16 weeks continuous (wound healing requires sustained LL-37 presence)
- Monitoring: Weekly photographic documentation, wound measurements at days 7, 14, 21, 28
- Expected Timeline:
- Day 7: Increased granulation tissue formation
- Day 14–21: Measurable reduction in wound area
- Day 28+: Sustained epithelialization and closure
- Endpoint: Discontinue once wound fully closed; taper is not necessary
Topical-Injection Combination (Accelerated Healing):
- 250 mcg injection daily + 0.5% topical cream to wound twice daily
- Increases local and systemic LL-37 delivery
- Expected improvement 20–30% faster than topical or injection alone
Primary Indication: Recurrent skin infections, chronic respiratory infections, microbiome recovery
Protocol:
- Dose: 200–300 mcg daily injection
- Cycle Length: 8–12 weeks on, 4 weeks off
- On-Cycle: 250 mcg daily for days 1–56
- Break: 4 weeks (28 days) with no LL-37
- Restart: Repeat for 3–4 cycles
Rationale for Cycling:
- Prevents downregulation of endogenous LL-37 production
- Maintains immune responsiveness
- Reduces pro-inflammatory adaptation
Signs of Efficacy:
- Reduced infection frequency (fewer flare-ups per cycle)
- Faster resolution of localized infections
- Improved wound closure in concurrent injuries
Primary Indication: Chronic inflammatory conditions, post-infection recovery, sepsis prevention
Protocol:
- Dose: 150–250 mcg daily injection
- Cycle Length: 12 weeks on, 2 weeks off
- Titration: Start at 150 mcg for days 1–7, increase to 250 mcg for days 8–84
Biomarkers to Track:
- High-sensitivity CRP
- TNF-α, IL-6 (if accessible)
- Monitoring should occur at baseline, week 4, week 8, week 12
Important Consideration: LL-37 is immunomodulatory and context-dependent. In autoimmune conditions, observe carefully for flares; if observed, reduce dose by 50% or discontinue.
Primary Indication: Post-MI recovery, metabolic health, hepatic steatosis prevention
Protocol:
- Dose: 200–300 mcg daily injection
- Cycle Length: 16 weeks continuous
- Frequency: Once daily, morning preferred
- Discontinuation: Gradual taper over 2 weeks (reduce by 50 mcg every 3–4 days)
Rationale: Cardiovascular and metabolic effects appear to require sustained dosing; abrupt cessation may lose benefits.
Concurrent Monitoring:
- Lipid panel (total cholesterol, LDL, HDL, triglycerides)
- Fasting glucose, HbA1c
- Liver function tests (AST, ALT) if assessing hepatic fat
- Cardiovascular event tracking (if post-MI population)
- Prepare the site: Clean injection area with alcohol swab; allow 30 seconds to air-dry
- Load the syringe: Draw the calculated volume from reconstituted vial using sterile technique
- Pinch the skin: Create a fold of skin between thumb and forefinger
- Insert needle: At 45° angle, insert needle quickly but smoothly into adipose tissue (not muscle)
- Inject solution: Push plunger slowly and steadily over 5–10 seconds
- Withdraw: Remove needle at the same angle of insertion
- Apply pressure: Hold sterile gauze at site for 10–15 seconds; do not rub
- Dispose: Use sharps container; never re-use needles
Optimal Sites (Rotate Daily):
- Lower abdomen (2 inches lateral to umbilicus)
- Anterior thigh (mid-outer quadriceps)
- Upper arm (lateral deltoid region)
- Rotate between all four sites to prevent lipohypertrophy
- Clean wound: Gently cleanse with sterile saline or wound cleanser
- Pat dry: Use sterile gauze; avoid excessive rubbing
- Apply LL-37 cream: Dispense 0.5–1 gram directly onto wound or surrounding tissue
- Massage gently: Work into skin using circular motions for 30–60 seconds
- Wait before covering: Allow 2–3 minutes before applying dressing or bandage
- Document: Photograph wound, note color/consistency of exudate, measure perimeter
- Clear nasal passages: Gently blow nose or use saline rinse
- Prime spray: If first use, prime pump 2–3 times away from face
- Insert nozzle: Place spray tip just inside nostril (not deeply inserted)
- Spray: Press down firmly once per nostril; sniff gently to distribute
- Wait: Do not blow nose immediately; allow 2–3 minutes for absorption
| Week | Dose (mcg) | Frequency | Route | Notes |
|---|
| 1–4 | 250 | Daily | Injection | Baseline wound assessment; expect initial granulation formation |
| 5–8 | 250 | Daily | Injection + Topical | Add 0.5% cream twice daily; increased healing velocity expected |
| 9–12 | 250 | Daily | Injection | Continue injection; reduce topical if wound >50% closed |
| 13–16 | 250 | Daily | Injection | Taper if wound >90% closed; discontinue upon full closure |
Measurement Protocol:
- Days 1, 7, 14, 21, 28: Wound area, depth, granulation index
- Weekly: Photography, patient-reported pain/drainage
- End-of-cycle: Final assessment; if >50% closure, continue second cycle at same dose
- Injection site reactions: Mild redness, warmth, slight swelling (resolves in 2–6 hours)
- Systemic response: None typically; may note increased salivation or mild oral sensations with nasal use
- Sensation: Topical applications may produce transient burning or stinging (30–60 seconds)
- Local effects: Wound tissue becomes more vascularized (increased red/pink coloring)
- Granulation: Increased tissue proliferation visible at wound edges
- Immune markers: Localized warmth and mild edema (indicates immune recruitment)
- Wound closure: Measurable reduction in wound area (typically 20–40% by week 4)
- Epithelialization: New skin growth visible at wound periphery
- Systemic inflammation (if applicable): Potential mild rise in inflammatory markers before decline (expected immunomodulatory peak)
- Accelerated healing: Closure rate increases if combining injection + topical
- Stabilization: Inflammation markers return to baseline or below
- Tissue quality: Scar formation visible; strength of healed tissue improves
- Plateau phase: Healing trajectory stabilizes
- If continuing: Diminishing returns; assess cost-benefit of continuation
- If discontinuing: Healing momentum typically continues for 2–4 weeks post-cessation
Problem: Starting at 500 mcg daily or increasing by 100 mcg every 2–3 days
Consequence: Exaggerated immune flare, pro-inflammatory response, potential rosacea or psoriasis exacerbation
Fix: Begin at 150–200 mcg; increase by 50 mcg every 1–2 weeks
Problem: Injecting the same abdomen location repeatedly
Consequence: Lipohypertrophy, reduced absorption, local inflammatory nodules
Fix: Use 4-site rotation system; same site no more than once per week
Problem: Administering LL-37 daily for 24+ weeks without off-cycles
Consequence: Potential downregulation of endogenous LL-37 synthesis; diminishing return on immune effects
Fix: Implement 2–4 week breaks per 12-week on-cycle for systemic immune protocols
Problem: Discontinuing after 2–4 weeks due to lack of immediate results
Consequence: Insufficient LL-37 tissue concentration; benefits never manifest
Fix: Commit to minimum 8-week cycles; wound healing requires 12–16 weeks
Problem: Using incorrect bacteriostatic water ratio; inconsistent micrograms per injection
Consequence: Dose variability; unreliable results; increased side effects from accidental overdose
Fix: Pre-calculate exact reconstitution volume; use calibrated syringes (0.1 mL increments minimum)
Problem: Using LL-37 in patients with active rheumatoid arthritis, lupus, or Crohn's disease without medical oversight
Consequence: Immune flare; exacerbation of symptoms
Fix: Absolute contraindication in uncontrolled autoimmune disease; proceed only with physician guidance
Rationale: Vitamin D3 upregulates endogenous LL-37 expression; combined approach amplifies antimicrobial and immunomodulatory effects
Protocol:
- LL-37: 250 mcg daily injection
- Vitamin D3: 4,000–5,000 IU daily (oral)
- Duration: 12 weeks continuous
- Rationale: Vitamin D increases serum LL-37 levels; combination shows superior sepsis outcomes in human data
Rationale: Growth hormone promotes tissue repair and collagen synthesis; LL-37 promotes angiogenesis and immune recruitment
Protocol (Wound Healing):
- LL-37: 250 mcg daily injection
- GHRP-6 or CJC-1295: 2–10 mcg daily (separate injection)
- Duration: 12 weeks
- Timing: LL-37 in morning; GHRP-6 in evening (minimizes interference)
Rationale: Sodium butyrate promotes endogenous LL-37 expression in intestinal epithelium; useful for gut health and microbiome recovery
Protocol:
- LL-37: 200 mcg daily injection
- Sodium butyrate: 1.5–2g daily (oral, enteric-coated)
- Duration: 8 weeks
- Notes: Allow 4-hour separation between administrations
LL-37 + Other Immunomodulatory Peptides (e.g., TB500, BPC-157): Risk of excessive immune activation and unpredictable cytokine responses. If stacking, reduce each dose by 30–50%.
LL-37 + Systemic Corticosteroids: Corticosteroids suppress endogenous LL-37; antagonistic interaction. Space administration by at least 12 hours if unavoidable.
| Goal | Dose (mcg) | Frequency | Route | Cycle Length | Break | Evidence Tier |
|---|
| Wound Healing | 250 | Daily | Injection ± Topical | 12–16 weeks | None (discontinue on closure) | 3 |
| Antimicrobial/Immune | 200–300 | Daily | Injection | 8–12 weeks on | 4 weeks off | 2 |
| Anti-Inflammatory | 150–250 | Daily | Injection | 12 weeks on | 2 | |